Can-Fite BioPharma (NYSE American: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, provided an update on its clinical program for Namodenoson in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. A pivotal Phase III registration study is open for enrollment of the most advanced liver cancer patients. At two upcoming bio-partnering conferences, Can-Fite will be presenting the latest data comparing the response of liver cancer patients to those with HCC Child-Pugh B (CPB), the most advanced liver cancer. The Company will also share the latest findings on a CPB liver cancer patient who remains cancer-free 6 years after she began treatment with Namodenoson.

Sharps Technology (Nasdaq: STSS), an innovative medical device and drug delivery company offering patented, best-in-class syringe products, has commenced manufacturing of their much-needed ultra-low waste smart safety syringe products through their European operation in Hungary. The plant has been producing products and began shipments to support the distribution and sales agreement with Nephron Pharmaceuticals at the end of 2022, and will commence shipments for customer agreements in Europe in early 2023. The production of these specialty syringe products will ramp up over the next several months to increase supply.

Nutriband (Nasdaq: NTRB), has begun production of its AI Tape brand with an expected launch of the product line in Q1 2023. AI Tape is designed to share many of the benefits of traditional Kinesiology Tape with added soothing and therapeutic ingredients held in suspension with a proprietary adhesive mix.

Greenwich Life Sciences (Nasdaq: GLSI), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, provided a year-end update on its Phase 3 clinical trial, Flamingo-01, evaluating the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2/neu positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment.